Value Of BioPharma M&A Leaps in Q3
Roche Tops Big Pharma Alliances
Merck & Co's proposed acquisition of Acceleron and a couple of big purchases from Sanofi drove up the value of the sector's M&A activities, according to the latest report from Biomedtracker
You may also be interested in...
Deal Watch: Merck Looks To Technology Platform Partners For Cytokine Agonist Discovery, Drug Delivery
Plus deals involving Moderna/Metagenomi, Agomab/Origo, Selecta/Ginkgo, Teva/MODAG, Boehringer Ingelheim/Thoeris and X-Chem/ComInnex/Glamorous AI.
Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.